Armata Pharmaceuticals, Inc.
ARMPArmata Pharmaceuticals, Inc. in brief
Armata Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Los Angeles, California, USA. Its market value was $130 M on 28 October 2026, which makes it the 17,794th largest listed company in the world and the 3,382nd largest in the USA on this site. It employs about 61 people and Deborah Birx is its chief executive. Its shares trade under the symbol ARMP (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Armata Pharmaceuticals, Inc.
We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date.
We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages” have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or “superbug” strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity and potency, and believe we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.
From the company's annual report filed with the US SEC: read the report
Armata Pharmaceuticals, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed AmpliPhi Biosciences CorpFormerly Targeted Genetics Corp /Wa/.
- 2019
- ✎Renamed Armata Pharmaceuticals, Inc.Formerly AmpliPhi Biosciences Corp.
Events of Armata Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,314 (Jan 2020) · #4,000 (Jan 2021) · #4,029 (Jan 2022) · #4,836 (Dec 2022) · #4,332 (Jul 2023) · #3,599 (Jan 2024) · #1,380 (Mar 2026) · #3,178 (Aug 2026) · #3,313 (Oct 2026) · #3,386 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -20.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 384.3%
- Revenue growth
- +412.5%
- R&D / revenue
- 1414.6%
- Profit per employee
- $-2.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-37M | $-174M | — |
| Dec 2024 | — | — | $-42M | $-19M | — |
| Dec 2023 | — | — | $-41M | $-69M | — |
| Dec 2022 | — | — | $-37M | $-37M | — |
| Dec 2021 | — | — | $-24M | $-23M | — |
| Dec 2020 | — | — | $-22M | $-22M | — |
| Dec 2019 | — | — | $-20M | $-19M | — |
| Dec 2018 | — | — | $-18M | $-17M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-26M | $1M | $-26M | $-4.80 | — |
| Dec 2024 | $-38M | $2M | $-39M | $-0.89 | — |
| Dec 2023 | $-47M | $8M | $-56M | $-1.91 | — |
| Dec 2022 | $-32M | $2M | $-35M | $-1.08 | — |
| Dec 2021 | $-24M | $1M | $-25M | $-0.96 | — |
| Dec 2020 | $-18M | $1M | $-19M | $-1.35 | — |
| Dec 2019 | $-16M | $0M | $-16M | $-2.55 | — |
| Dec 2018 | $-11M | $1M | $-12M | $-3.59 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $55M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 23, 20268-KCurrent reportOther events
- Sep 14, 20268-KCurrent reportRegulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jul 20, 20268-KCurrent reportRegulation FD disclosure
- Jul 20, 20268-KCurrent reportDirectors or officers changed
- Jul 13, 20268-KCurrent reportRegulation FD disclosure
- Jun 24, 20268-K/ACurrent report (amended)Directors or officers changed
- Jun 23, 20268-KCurrent reportOther events
- Jun 16, 20268-KCurrent reportShareholder vote
Official filings of Armata Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-37 M
- Net income
- $-174 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $77 M
- Total liabilities
- $295 M
- Total equity
- $-219 M
As of December-2025
Top 64 institutional investors in Armata Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Madison Asset Management, LLC | 2,107,175 | 0 (0.00%) | 5.67% | $8 M | Nov 12, 2026 |
| 2 | Millennium Management LLC | 1,054,231 | +583,731 (+124.07%) | 2.83% | $4 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 558,226 | -1,760 (-0.31%) | 1.50% | $2 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 487,968 | 0 (0.00%) | 1.31% | $2 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 278,544 | +7,994 (+2.95%) | 0.75% | $1 M | Nov 6, 2026 |
| 6 | State Street Corp | 184,501 | +54,901 (+42.36%) | 0.50% | $1 M | Nov 12, 2026 |
| 7 | Grey Ledge Advisors, LLC | 100,000 | +50,000 (+100.00%) | 0.27% | $0 M | Nov 2, 2026 |
| 8 | Northern Trust Corp | 90,571 | +780 (+0.87%) | 0.24% | $0 M | Nov 16, 2026 |
| 9 | Vanguard Portfolio Management LLC | 81,579 | +225 (+0.28%) | 0.22% | $0 M | Nov 13, 2026 |
| 10 | Edgewood Management LLC | 80,000 | 0 (0.00%) | 0.22% | $0 M | Nov 12, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 79,385 | -110 (-0.14%) | 0.21% | $0 M | Nov 13, 2026 |
| 12 | UBS Group AG | 54,374 | +40,677 (+296.98%) | 0.15% | $0 M | Nov 10, 2026 |
| 13 | Bridgeway Capital Management, LLC | 43,988 | -694 (-1.55%) | 0.12% | $0 M | Nov 16, 2026 |
| 14 | SeaCrest Wealth Management, LLC | 41,899 | +375 (+0.90%) | 0.11% | $0 M | Oct 21, 2026 |
| 15 | Empowered Funds, LLC | 40,688 | New | 0.11% | $0 M | Nov 13, 2026 |
| 16 | Renaissance Technologies LLC | 34,653 | -13,665 (-28.28%) | 0.09% | $0 M | Nov 12, 2026 |
| 17 | Bank of New York Mellon Corp | 30,559 | +810 (+2.72%) | 0.08% | $0 M | Nov 5, 2026 |
| 18 | Charles Schwab Investment Management Inc | 28,863 | +6 (+0.02%) | 0.08% | $0 M | Nov 16, 2026 |
| 19 | XTX Topco Ltd | 27,867 | +17,041 (+157.41%) | 0.07% | $0 M | Nov 16, 2026 |
| 20 | Goldman Sachs Group Inc | 25,156 | New | 0.07% | $0 M | Nov 16, 2026 |
| 21 | Hudson Bay Capital Management LP | 17,584 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 22 | Nuveen, LLC | 17,545 | +1,640 (+10.31%) | 0.05% | $0 M | Nov 10, 2026 |
| 23 | Susquehanna International Group, LLP | 15,913 | New | 0.04% | $0 M | Nov 16, 2026 |
| 24 | New York State Common Retirement Fund | 15,400 | 0 (0.00%) | 0.04% | $0 M | Nov 17, 2026 |
| 25 | Price T Rowe Associates Inc /MD/ | 15,330 | New | 0.04% | $0 M | Nov 16, 2026 |
Show all 64: investors 26 to 64
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Bank Of America Corp /de/ | 14,484 | +3,179 (+28.12%) | 0.04% | $0 M | Nov 16, 2026 |
| 27 | Nisa Investment Advisors, LLC | 13,650 | New | 0.04% | $0 M | Oct 20, 2026 |
| 28 | Captrust Financial Advisors | 13,238 | +98 (+0.75%) | 0.04% | $0 M | Nov 12, 2026 |
| 29 | Deutsche Bank AG\ | 11,593 | -373 (-3.12%) | 0.03% | $0 M | Nov 6, 2026 |
| 30 | Dauntless Investment Group, LLC | 9,105 | -194,786 (-95.53%) | 0.02% | $0 M | Nov 16, 2026 |
| 31 | Rhumbline Advisers | 8,177 | -276 (-3.27%) | 0.02% | $0 M | Nov 10, 2026 |
| 32 | Police & Firemen's Retirement System of New Jersey | 6,095 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 33 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 5,729 | +268 (+4.91%) | 0.02% | $0 M | Nov 16, 2026 |
| 34 | Jpmorgan Chase & Co | 5,617 | +701 (+14.26%) | 0.02% | $0 M | Nov 12, 2026 |
| 35 | Morgan Stanley | 5,412 | +829 (+18.09%) | 0.01% | $0 M | Nov 13, 2026 |
| 36 | Barclays PLC | 5,122 | +2,138 (+71.65%) | 0.01% | $0 M | Nov 6, 2026 |
| 37 | Russell Investments Group, Ltd. | 4,503 | +3,534 (+364.71%) | 0.01% | $0 M | Nov 6, 2026 |
| 38 | Vanguard Global Advisers, LLC | 4,022 | +58 (+1.46%) | 0.01% | $0 M | Nov 13, 2026 |
| 39 | Wells Fargo & Company/mn | 3,605 | -7,214 (-66.68%) | 0.01% | $0 M | Nov 16, 2026 |
| 40 | BNP Paribas Financial Markets | 3,579 | +541 (+17.81%) | 0.01% | $0 M | Nov 12, 2026 |
| 41 | Royal Bank Of Canada | 2,753 | +2,256 (+453.92%) | 0.01% | $0 M | Nov 16, 2026 |
| 42 | Tower Research Capital LLC (TRC) | 2,524 | +490 (+24.09%) | 0.01% | $0 M | Nov 16, 2026 |
| 43 | Cornerstone National Bank & Trust Co | 1,428 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 44 | FMR LLC | 1,415 | +1,051 (+288.74%) | 0.00% | $0 M | Nov 10, 2026 |
| 45 | Legal & General Group Plc | 1,161 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 46 | Ameritas Investment Partners, Inc. | 1,076 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 47 | Measured Wealth Private Client Group, LLC | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 48 | Trifecta Capital Advisors, LLC | 714 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
| 49 | Farther Finance Advisors, LLC | 597 | New | 0.00% | $0 M | Oct 8, 2026 |
| 50 | Citigroup Inc | 589 | -5,014 (-89.49%) | 0.00% | $0 M | Nov 4, 2026 |
| 51 | Northwestern Mutual Wealth Management Co | 571 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 52 | GAMMA Investing LLC | 550 | New | 0.00% | $0 M | Oct 8, 2026 |
| 53 | Sterling Capital Management LLC | 389 | +347 (+826.19%) | 0.00% | $0 M | Oct 22, 2026 |
| 54 | Caitong International Asset Management Co., Ltd | 219 | New | 0.00% | $0 M | Oct 29, 2026 |
| 55 | Silver Grove Financial Group, Inc. | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 56 | Simplex Trading, LLC | 183 | -611 (-76.95%) | 0.00% | $0 M | Nov 4, 2026 |
| 57 | Arax Advisory Partners | 138 | New | 0.00% | $0 M | Nov 12, 2026 |
| 58 | Whittier Trust Co | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 59 | North Star Investment Management Corp. | 99 | New | 0.00% | $0 M | Oct 27, 2026 |
| 60 | Team Financial Group, LLC | 71 | New | 0.00% | $0 M | Oct 30, 2026 |
| 61 | EverSource Wealth Advisors, LLC | 13 | New | 0.00% | $0 M | Nov 4, 2026 |
| 62 | SBI Securities Co., Ltd. | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 63 | Allworth Financial LP | 1 | New | 0.00% | $0 M | Nov 17, 2026 |
| 64 | IFP Advisors, Inc | 1 | New | 0.00% | $0 M | Oct 16, 2026 |
Mutual funds holding Armata Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 349,598 | $2 M | 0.94% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 197,072 | $1 M | 0.53% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 125,873 | $1 M | 0.34% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 111,368 | $1 M | 0.30% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 128,856 | $1 M | 0.35% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 56,701 | $0 M | 0.15% | <0.01% | −2.7% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 41,382 | $0 M | 0.11% | 0.18% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 39,743 | $0 M | 0.11% | 0.02% | +47% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 22,168 | $0 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 17,296 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 16,271 | $0 M | 0.04% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 28,857 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 11,252 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 11,164 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 15,905 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 9,700 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 7,181 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 6,700 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 6,118 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 5,316 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 5,649 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,826 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,267 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,628 | $0 M | <0.01% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,478 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,840 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,796 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,703 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,076 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,044 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 969 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,389 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,328 | $0 M | <0.01% | <0.01% | +5.1% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 830 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 830 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,178 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 779 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 907 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 406 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Armata Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Deborah BirxChief Executive Officer, Director | Shares withheld for tax | -14,041 | $4.260 | $60 K | 198,417 | Form 4 |
| filed | Pierre KymeChief Business Officer | Shares withheld for tax | -1,030 | $10.54 | $11 K | 9,461 | Form 4 |
| filed | Deborah BirxChief Executive Officer, Director | Shares withheld for tax | -4,919 | $10.54 | $52 K | 212,458 | Form 4 |
| filed | Deborah BirxChief Executive Officer, Director | Shares withheld for tax | -13,637 | $2.270 | $31 K | 217,377 | Form 4 |
| filed | Pierre KymeChief Business Officer | Shares withheld for tax | -1,027 | $1.950 | $2 K | 10,491 | Form 4 |
| filed | Deborah BirxChief Executive Officer, Director | Shares withheld for tax | -6,061 | $1.950 | $12 K | 231,014 | Form 4 |
| filed | Deborah BirxChief Executive Officer, Director | Shares withheld for tax | -22,925 | $2.680 | $61 K | 237,075 | Form 4 |
| filed | Deborah BirxChief Executive Officer, Director | Grant or award | +60,000 | — | — | 260,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Armata Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-14.01 reverse split in the period to ; 1-for-14.01 reverse split ; 10-for-1 split ; 50-for-1 split
Trading halts
- 2025-11-10 15:11 UTC, code M, resumed 15:16 UTC
- 2025-11-10 15:05 UTC, code M, resumed 15:10 UTC
- 2025-10-22 18:23 UTC, code M, resumed 18:28 UTC
- 2025-10-22 18:17 UTC, code M, resumed 18:22 UTC
- 2025-10-22 18:08 UTC, code M, resumed 18:13 UTC
Fails to deliver
- : 1,464 shares at $3.49
- : 1,460 shares at $3.81
- : 4,316 shares at $3.31
- : 2,905 shares at $3.67
- : 2,318 shares at $3.59
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Armata Pharmaceuticals, Inc. scorecard#
Passes 2 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-20.3%Free cash flow is -20.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.80 vs -0.89Diluted EPS -4.80 in fiscal 2025 against -0.89 the year before (report's currency).
- ✗Net income higher than five years earlier-$174 M-$174 M in fiscal 2025 against -$22 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$174 MNet income -$174 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.19 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-38.6%Diluted shares down 38.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Armata Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 24−31.1%— | 34+1.9%— | 34−3.6%— | 35+75.0%— | 20+38.6%— | 14+47.0%— | 9.8+17.3%— | 8.4r4.9+191%— | 2.9−49.3%— | 5.7—— | |
| General and administrative | 12−5.9%— | 13+13.2%— | 12+56.6%— | 7.4−10.2%— | 8.3+4.0%— | 8.0−14.0%— | 9.3+268%— | 2.5r5.7−66.8%— | 7.6−9.8%— | 8.4—— | |
| Operating expenses | 42−12.8%— | 48+4.8%— | 45+7.0%— | 42+50.0%— | 28+26.3%— | 22+13.5%— | 20+11.9%— | 18r13+8.5%— | 16−31.2%— | 24—— | |
| Operating income | −37—— | −42—— | −41—— | −37—— | −24—— | −22—— | −20—— | −18r−13—— | −16—— | −23—— | |
| Interest and finance income | — | — | 0.2+517%— | 0.0+480%— | 0.0−82.1%— | 0.0−70.8%— | 0.1−60.8%— | 0.2—— | — | — | |
| Interest expense and finance costs | — | — | 2.6—— | 0−100%— | 0.1−89.8%— | 0.6−32.5%— | 0.9−8.1%— | 1.0—— | — | 0.0—— | |
| Other non-operating income (expense) | −137−683%— | 24—— | −28−97186%— | 0.0−95.7%— | 0.7—— | −0.6−318%— | 0.3−71.4%— | 1.0r0.1−52.6%— | 2.0−49.4%— | 4.0—— | |
| Income before tax | −174—— | −19—— | −69r−0.1—— | −0.0r−37—— | −23—— | −22—— | −19—— | −17r−12—— | −14—— | −19—— | |
| Income tax | — | — | — | — | — | — | — | −0.3—— | −1.3—— | −0.6—— | |
| Net income including minority interests | −174—— | −19—— | −69—— | −37—— | −23—— | −22—— | −19—— | −17—— | — | — | |
| Net income attributable to shareholders | −174—— | −19—— | −69—— | −37—— | −23—— | −22—— | −19—— | −17r−12—— | −13—— | −19—— | |
| Earnings per share, basic | -4.80—— | -0.52—— | -1.91—— | -1.08—— | -0.96—— | -1.35—— | -2.49—— | -3.59r-0.64—— | -2.01—— | -24.67r-2.47—— | |
| Earnings per share, diluted | -4.80—— | -0.89—— | -1.91—— | -1.08—— | -0.96—— | -1.35—— | -2.55—— | -3.59r-0.64—— | -2.18—— | -24.67r-2.47—— | |
| Shares, weighted average (basic) | 36+0.2%— | 36+0.2%— | 36+5.2%— | 34+42.3%— | 24+46.8%— | 16+110%— | 7.8+68.2%— | 4.7r19−27.2%— | 6.4+549%— | 1.0—— | |
| Shares, weighted average (diluted) | 36−38.6%— | 59+63.7%— | 36+5.2%— | 34+42.3%— | 24+46.8%— | 16+105%— | 8.0+72.2%— | 4.7r19−29.2%— | 6.6+568%— | 1.0r9.8—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.7−6.5%11.3% | 9.3−31.3%10.7% | 14−8.9%13.7% | 15+44.4%15.5% | 10+6.6%14.7% | 9.6+59.9%24.4% | 6.0−37.6%23.7% | 9.7r8.2+88.3%66.4% | 5.10.0%46.1% | 5.1r5.7—28.3% | |
| Receivables | — | — | — | — | — | — | — | — | — | 0.0r0.0—0.1% | |
| Other current assets | 0.5−36.6%0.6% | 0.7−77.9%0.9% | 3.4−60.6%3.4% | 8.5r10+397%8.9% | 1.7+170%2.5% | 0.6+2.3%1.6% | 0.6−10.8%2.4% | 0.7r0.3+175%4.8% | 0.3−58.0%2.3% | 0.6r0.6—3.3% | |
| Current assets | 11−5.7%13.9% | 11−41.0%13.1% | 19−29.2%19.5% | 27+80.4%28.2% | 15+38.3%21.5% | 11+63.0%27.4% | 6.7−35.8%26.1% | 10r8.4+92.4%71.2% | 5.4−14.7%48.3% | 6.3r6.4—34.8% | |
| Property, plant and equipment | 12−7.9%15.9% | 13+5.4%15.3% | 13+247%12.8% | 3.6+62.9%3.8% | 2.2+8.5%3.2% | 2.0−6.4%5.2% | 2.2−32.7%8.6% | 3.2r0.5+298%22.3% | 0.8−23.9%7.3% | 1.1—5.9% | |
| Right-of-use (leased) assets | 34−18.7%44.1% | 42−6.8%48.2% | 45+3.9%45.5% | 43+20.0%44.9% | 36+232%51.4% | 11+432%27.3% | 2.0—8.0% | — | — | — | |
| Goodwill | 3.50.0%4.5% | 3.50.0%4.0% | 3.50.0%3.5% | 3.50.0%3.6% | 3.50.0%5.0% | 3.50.0%8.8% | 3.5—13.7% | — | — | — | |
| Other intangible assets | 100.0%13.3% | 100.0%11.9% | 100.0%10.4% | 100.0%10.7% | 100.0%14.7% | 100.0%26.0% | 10+276%40.3% | 2.7−41.4%18.8% | 4.7−55.4%41.8% | 10—57.6% | |
| Total assets | 77−11.1%100% | 86−12.1%100% | 98+2.6%100% | 96+37.4%100% | 70+76.6%100% | 40+55.3%100% | 25+75.0%100% | 15r12+30.6%100% | 11−38.6%100% | 18r18—100% | |
| Accounts payable | 0.9+20.2%1.2% | 0.8−51.7%0.9% | 1.6−5.5%1.6% | 1.7r1.7+47.5%1.8% | 1.1r1.1+19.0%1.6% | 1.0r1.0+74.8%2.4% | 0.5r0.5+31.8%2.1% | 0.4r0.7−28.2%2.9% | 0.6−45.3%5.2% | 1.1r1.7—5.8% | |
| Current liabilities | 8.9−81.5%11.6% | 48+193%55.8% | 16−33.8%16.7% | 25+417%26.0% | 4.8−28.2%6.9% | 6.7+37.4%17.0% | 4.9+140%19.2% | 2.0r2.6+3.3%14.0% | 2.0−44.4%17.7% | 3.5r3.6—19.5% | |
| Lease liabilities (non-current) | 27−4.2%34.5% | 28−3.1%32.0% | 29−10.1%29.1% | 32−12.8%33.2% | 36+235%52.3% | 11+599%27.5% | 1.6—6.1% | — | — | — | |
| Total liabilities | 295+120%384% | 134+3.1%156% | 130+118%133% | 60+34.7%62.4% | 44+115%63.6% | 21+90.3%52.3% | 11+58.5%42.7% | 6.9r3.4+101%47.1% | 3.4−59.6%30.6% | 8.4r8.5—46.4% | |
| Retained earnings | −502—−652% | −328—−379% | −309—−314% | −240—−250% | −203—−291% | −180—−455% | −158—−619% | −138r−406—−949% | −394—−3539% | −381—−2101% | |
| Shareholders' equity | −219—−284% | −48—−55.6% | −32−189%−32.6% | 36+42.1%37.6% | 25+34.7%36.4% | 19+29.2%47.7% | 15+89.7%57.3% | 7.7r8.5−68.4%52.9% | 24r7.7+150%219% | 9.7—53.6% | |
| Total liabilities and equity | 77−11.1%100% | 86−12.1%100% | 98+2.6%100% | 96+37.4%100% | 70+76.6%100% | 40+55.3%100% | 25+75.0%100% | 15r12+30.6%100% | 11−38.6%100% | 18r18—100% | |
| Shares outstanding | 36+0.7%— | 36+0.2%— | 36−0.1%— | 36+33.3%— | 27+45.1%— | 19+88.3%— | 9.9+95.7%— | 5.1r32−46.6%— | 9.5+476%— | 1.6r16—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 1.3+36.3%— | 1.0+9.0%— | 0.9—— | — | — | — | — | — | — | |
| Share-based compensation | 2.6−9.8%— | 2.9+208%— | 0.9−69.8%— | 3.1+7.7%— | 2.9−17.1%— | 3.5−18.6%— | 4.3+9185%— | 0.0r0.5−93.4%— | 0.7−64.9%— | 2.0—— | |
| Cash from operating activities | −26—— | −38—— | −47—— | −32—— | −24—— | −18—— | −16—— | −11r−9.4—— | −9.2—— | −11r−11—— | |
| Capital expenditure | −0.5—— | −1.9—— | −8.1—— | −2.2—— | −1.3—— | −0.8—— | −0.2—— | −0.9r−0.0—— | −0.1—— | −0.3—— | |
| Cash from investing activities | −0.5—— | −1.9—— | −8.1—— | −2.2—— | −1.3—— | −0.8−129%— | 2.9−67.4%— | 8.8r−0.0—— | −0.1—— | −0.3—— | |
| Shares issued | — | — | — | 44+68.7%— | 26+15.0%— | 23+130%— | 10.0—— | — | — | — | |
| Dividends paid | — | — | — | — | — | — | — | — | — | −0.1—— | |
| Cash from financing activities | 26−26.7%— | 35−35.2%— | 54+22.7%— | 44+72.5%— | 26+9.9%— | 23+159%— | 9.0−27.9%— | 12+43.6%— | 8.7+20.0%— | 7.2r7.2—— | |
| Change in cash | −0.7—— | −4.5—— | −1.6−117%— | 9.3+1359%— | 0.6−84.5%— | 4.1—— | −3.7—— | −1.8r3.0—— | −0.6—— | −3.7—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 27+1.9%— | 6.8+17.3%— | 7.6+18.6%— | 6.1+12.6%— | 6.1*−28.2%— | 5.8−38.6%— | 6.4−24.6%— | 5.4−32.3%— | 8.5*+6.6%— | 9.5—— | 8.5—— | 8.0—— | 7.9*—— | |
| General and administrative | 16+28.8%— | 3.7+19.7%— | 5.2+99.9%— | 3.5+6.5%— | 3.4*+3.1%— | 3.1−4.1%— | 2.6−23.8%— | 3.3+2.4%— | 3.3*+4.5%— | 3.2—— | 3.4—— | 3.2—— | 3.2*—— | |
| Operating expenses | 48+24.6%— | 11+18.1%— | 13+42.3%— | 9.6+10.3%— | 15*+26.6%— | 8.9−29.8%— | 9.0−24.3%— | 8.7−22.4%— | 12*+6.0%— | 13—— | 12—— | 11—— | 11*—— | |
| Operating income | −40—— | −7.4—— | −10—— | −8.8—— | −14*—— | −7.8—— | −6.8—— | −8.2—— | −11*—— | −9.8—— | −12—— | −10—— | −9.6*—— | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | — | 0.2—— | 0.1—— | 0.1*—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | 2.7—— | 1.8—— | — | |
| Other non-operating income (expense) | −70—— | 62—— | 84—— | −107−6519%— | −110*−941%— | −19−542%— | −9.5−145%— | 1.7—— | 13*—— | 4.3—— | 21—— | −15—— | −10*—— | |
| Income tax | — | 0—— | 0*—— | 0—— | — | 0—— | 0*—— | 0—— | — | 0—— | 0—— | 0—— | — | |
| Net income including minority interests | −111—— | 55*—— | 74*—— | −115—— | −124*−4881%— | −27*—— | −16*−281%— | −6.5—— | 2.6*—— | −5.5*—— | 9.0*—— | −25—— | −20*—— | |
| Net income attributable to shareholders | −111—— | 55—— | 74—— | −115—— | −124*−4881%— | −27—— | −16−281%— | −6.5—— | 2.6*—— | −5.5—— | 9.0—— | −25—— | −20*—— | |
| Earnings per share, basic | — | 1.15—— | 2.02—— | -3.16—— | — | -0.74—— | -0.45−280%— | -0.18—— | — | -0.15—— | 0.25—— | -0.69—— | — | |
| Earnings per share, diluted | — | -0.24—— | -0.27—— | -3.16—— | — | -0.74—— | -0.45—— | -0.20—— | — | -0.15—— | -0.25—— | -0.69—— | — | |
| Shares, weighted average (basic) | 37+2.6%— | 37+2.6%— | 37+1.5%— | 37+1.0%— | — | 36+0.1%— | 36+0.1%— | 36+0.2%— | — | 36—— | 36—— | 36—— | — | |
| Shares, weighted average (diluted) | 63+73.0%— | 63+73.0%— | 62+71.4%— | 37−38.6%— | — | 36+0.1%— | 36−37.9%— | 59+64.6%— | — | 36—— | 58—— | 36—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 18—21.7% | 18+24.1%21.7% | 24+453%26.6% | 4.8−59.3%6.8% | 8.7−6.5%11.3% | 15−13.9%16.5% | 4.3−83.6%5.4% | 12−69.1%13.4% | 9.3−31.3%10.7% | 17—17.4% | 26—24.4% | 38—31.5% | 14—13.7% | |
| Other current assets | 3.2—3.8% | 3.2+323%3.8% | 2.5+16.8%2.8% | 0.0−80.3%0.1% | 0.5−36.6%0.6% | 0.8−65.8%0.8% | 2.2+74.6%2.7% | 0.2−86.1%0.3% | 0.7−77.9%0.9% | 2.2—2.3% | 1.2—1.1% | 1.7—1.4% | 3.4—3.4% | |
| Current assets | 23—26.8% | 23+33.5%26.8% | 27+261%30.2% | 5.9−54.8%8.5% | 11−5.7%13.9% | 17−24.4%18.9% | 7.5−75.7%9.3% | 13−68.4%15.1% | 11−41.0%13.1% | 22—22.8% | 31—28.5% | 42—34.7% | 19—19.5% | |
| Property, plant and equipment | 11—12.8% | 11−14.0%12.8% | 11−11.3%12.5% | 12−8.6%16.9% | 12−7.9%15.9% | 13−7.8%14.0% | 13−6.1%15.7% | 13+1.4%14.8% | 13+5.4%15.3% | 14—13.9% | 13—12.4% | 13—10.6% | 13—12.8% | |
| Right-of-use (leased) assets | 32—38.3% | 32−18.9%38.3% | 33−18.8%36.6% | 33−18.7%47.8% | 34−18.7%44.1% | 40−5.5%44.6% | 41−7.3%50.1% | 41−7.1%47.1% | 42−6.8%48.2% | 42—43.0% | 44—40.3% | 44—36.8% | 45—45.5% | |
| Goodwill | 3.5—4.1% | 3.50.0%4.1% | 3.50.0%3.9% | 3.50.0%5.0% | 3.50.0%4.5% | 3.50.0%3.9% | 3.50.0%4.3% | 3.50.0%4.0% | 3.50.0%4.0% | 3.5—3.6% | 3.5—3.2% | 3.5—2.9% | 3.5—3.5% | |
| Other intangible assets | 10—12.1% | 100.0%12.1% | 100.0%11.4% | 100.0%14.7% | 100.0%13.3% | 100.0%11.5% | 100.0%12.7% | 100.0%11.8% | 100.0%11.9% | 10—10.4% | 10—9.5% | 10—8.5% | 10—10.4% | |
| Total assets | 84—100% | 84−5.6%100% | 90+11.3%100% | 70−20.0%100% | 77−11.1%100% | 90−8.9%100% | 81−25.4%100% | 87−27.5%100% | 86−12.1%100% | 98—100% | 108—100% | 120—100% | 98—100% | |
| Accounts payable | 0.6—0.7% | 0.6−54.1%0.7% | 1.2+23.6%1.3% | 0.7−32.7%0.9% | 0.9+20.2%1.2% | 1.3−29.5%1.4% | 1.0−44.6%1.2% | 1.0−52.3%1.1% | 0.8−51.7%0.9% | 1.8—1.8% | 1.7—1.6% | 2.1—1.7% | 1.6—1.6% | |
| Current liabilities | 187—221% | 187+33.5%221% | 250+108%278% | 9.2−91.7%13.2% | 8.9−81.5%11.6% | 140+18.4%156% | 120−2.5%149% | 111+0.4%127% | 48+193%55.8% | 118—120% | 123—114% | 110—91.4% | 16—16.7% | |
| Lease liabilities (non-current) | 25—30.1% | 25−5.2%30.1% | 26−4.8%28.7% | 26−4.5%37.5% | 27−4.2%34.5% | 27−3.9%30.0% | 27−3.6%33.6% | 27−3.4%31.4% | 28−3.1%32.0% | 28—28.4% | 28—26.0% | 28—23.6% | 29—29.1% | |
| Total liabilities | 259—306% | 259+39.7%306% | 321+114%357% | 381+170%546% | 295+120%384% | 185+24.1%207% | 150−2.7%186% | 141−20.3%162% | 134+3.1%156% | 149—152% | 154—143% | 177—147% | 130—133% | |
| Retained earnings | −488—−578% | −488—−578% | −543—−603% | −617—−884% | −502—−652% | −377—−421% | −351—−434% | −334—−383% | −328—−379% | −330—−336% | −325—−300% | −334—−277% | −309—−314% | |
| Shareholders' equity | −174—−206% | −174—−206% | −231—−257% | −312—−446% | −219—−284% | −96—−107% | −70—−86.0% | −54—−61.6% | −48—−55.6% | −51—−51.9% | −46—−42.6% | −57—−47.0% | −32—−32.6% | |
| Total liabilities and equity | 84—100% | 84−5.6%100% | 90+11.3%100% | 70−20.0%100% | 77−11.1%100% | 90−8.9%100% | 81−25.4%100% | 87−27.5%100% | 86−12.1%100% | 98—100% | 108—100% | 120—100% | 98—100% | |
| Shares outstanding | 37—— | 37+1.5%— | 37+2.6%— | — | 36+0.7%— | 37r3.6+1.3%— | 36+0.1%— | 36+0.2%— | 36+0.2%— | 36—— | 36—— | 36—— | 36—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | 0.4*+18.2%— | 0.4*+16.2%— | 0.4+18.9%— | 0.4*+29.7%— | 0.3*—— | 0.3*—— | 0.3—— | 0.3*—— | |
| Share-based compensation | 7.3+214%— | 2.2+256%— | 3.4+490%— | 1.1+37.6%— | 0.6*+78.5%— | 0.6−7.2%— | 0.6−56.9%— | 0.8+46.3%— | 0.4*+83.4%— | 0.7—— | 1.3—— | 0.5—— | 0.2*—— | |
| Cash from operating activities | −27—— | −5.5*—— | −8.7*—— | −5.8—— | −6.7*—— | −4.3*—— | −7.2*—— | −7.6—— | −7.9*—— | −8.9*—— | −10*—— | −11—— | −8.1*—— | |
| Capital expenditure | −0.2—— | −0.1*—— | −0.0*—— | −0.1—— | −0.1*—— | −0.2*—— | −0.1*—— | −0.1—— | — | −0.3*—— | −1.4*—— | −0.3—— | −2.4*—— | |
| Cash from investing activities | −0.2—— | −0.1*—— | −0.0*—— | −0.1—— | −0.1*−168%— | −0.2*—— | −0.1*—— | −0.1—— | 0.1*—— | −0.3*—— | −1.4*—— | −0.3—— | −2.4*—— | |
| Shares issued | — | 0*—— | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 29+16.8%— | −0.0*−100%— | 28*—— | 0.6−93.6%— | 0.7*—— | 15*—— | 0*−100%— | 10.0−71.4%— | 0*—— | −0.1*—— | 0.1*—— | 35—— | −0.0*—— | |
| Change in cash | 2.3—— | −5.6*−154%— | 19*—— | −5.2−326%— | −6.1*—— | 10*—— | −7.4*—— | 2.3−90.4%— | −7.9*—— | −9.3*—— | −11*—— | 24—— | −11*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Armata Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Birx | $1.2 M | $4.2 M | $673 K | $113 |
| 2024Deborah Birx | $1.8 M | $1.0 M | $636 K | $33 |
| 2023Deborah Birx | $1.1 M | $1.4 M | $316 K | $58 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Armata Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 4 · New debt 2 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Shareholder vote | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Armata Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$130 M · higher than 40% of 726
- Revenue growth412.5% · higher than 94% of 438
- FCF yield-20.3% · higher than 44% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Armata Pharmaceuticals, Inc.🇺🇸 | $130 M | — | — | +412.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 18, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Armata Pharmaceuticals, Inc.? Verify and update this profile — free
Show Armata Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.